Back to News
Market Impact: 0.2
Corvus Pharmaceuticals Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Corvus Pharmaceuticals reported third-quarter 2026 financial results and a clinical pipeline update. As of September 30, 2026, it held $202.9 million in cash, cash equivalents and marketable securities; the provided article text does not include further financial or pipeline details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Mizuho reiterates Corvus Pharmaceuticals stock rating on pipeline
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise